RU2017140678A3 - - Google Patents

Download PDF

Info

Publication number
RU2017140678A3
RU2017140678A3 RU2017140678A RU2017140678A RU2017140678A3 RU 2017140678 A3 RU2017140678 A3 RU 2017140678A3 RU 2017140678 A RU2017140678 A RU 2017140678A RU 2017140678 A RU2017140678 A RU 2017140678A RU 2017140678 A3 RU2017140678 A3 RU 2017140678A3
Authority
RU
Russia
Application number
RU2017140678A
Other versions
RU2750163C2 (ru
RU2017140678A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017140678A publication Critical patent/RU2017140678A/ru
Publication of RU2017140678A3 publication Critical patent/RU2017140678A3/ru
Application granted granted Critical
Publication of RU2750163C2 publication Critical patent/RU2750163C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D46/00Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D46/00Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B01D46/24Particle separators, e.g. dust precipitators, using rigid hollow filter bodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/08Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
    • B01J19/10Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/26Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008Processes carried out under supercritical conditions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/02Feed or outlet devices therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J4/00Feed or outlet devices; Feed or outlet control devices
    • B01J4/001Feed or outlet devices as such, e.g. feeding tubes
    • B01J4/002Nozzle-type elements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05BSPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05BSPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B05B1/3489Nozzles having concentric outlets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05BSPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B13/00Machines or plants for applying liquids or other fluent materials to surfaces of objects or other work by spraying, not covered by groups B05B1/00 - B05B11/00
    • B05B13/02Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work
    • B05B13/0278Arrangement or mounting of spray heads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2271/00Sealings for filters specially adapted for separating dispersed particles from gases or vapours
    • B01D2271/02Gaskets, sealings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2204/00Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices
    • B01J2204/002Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices the feeding side being of particular interest
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05DPROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2401/00Form of the coating product, e.g. solution, water dispersion, powders or the like
    • B05D2401/90Form of the coating product, e.g. solution, water dispersion, powders or the like at least one component of the composition being in supercritical state or close to supercritical state

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Filtering Of Dispersed Particles In Gases (AREA)
  • Glanulating (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nozzles (AREA)
RU2017140678A 2015-06-04 2016-06-06 Таксановые частицы и их применение RU2750163C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562171060P 2015-06-04 2015-06-04
US201562171008P 2015-06-04 2015-06-04
US201562171001P 2015-06-04 2015-06-04
US62/171,060 2015-06-04
US62/171,001 2015-06-04
US62/171,008 2015-06-04
PCT/US2016/035993 WO2016197091A1 (en) 2015-06-04 2016-06-06 Taxane particles and their use

Publications (3)

Publication Number Publication Date
RU2017140678A RU2017140678A (ru) 2019-07-09
RU2017140678A3 true RU2017140678A3 (ru) 2019-07-17
RU2750163C2 RU2750163C2 (ru) 2021-06-22

Family

ID=56194575

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017140678A RU2750163C2 (ru) 2015-06-04 2016-06-06 Таксановые частицы и их применение

Country Status (14)

Country Link
US (11) US10751319B2 (ru)
EP (4) EP3302780B1 (ru)
JP (5) JP6758325B2 (ru)
KR (5) KR20200134347A (ru)
CN (4) CN114010628A (ru)
AU (3) AU2016270559B2 (ru)
CA (3) CA2988132C (ru)
DK (1) DK3302431T3 (ru)
ES (1) ES2833749T3 (ru)
HK (3) HK1253020A1 (ru)
PT (1) PT3302431T (ru)
RU (1) RU2750163C2 (ru)
SG (2) SG10201913945QA (ru)
WO (3) WO2016197091A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3302431T3 (da) * 2015-06-04 2020-11-30 Crititech Inc Taxanpartikler og anvendelse deraf
EP3324930A2 (en) 2015-09-16 2018-05-30 DFB Soria, LLC Delivery of drug nanoparticles and methods of use thereof
RU2737934C2 (ru) 2016-04-04 2020-12-07 Крититек, Инк. Способы лечения солидных опухолей
EP3386719B1 (en) * 2016-05-12 2022-10-05 Hewlett-Packard Development Company, L.P. Build material container
CN110636833B (zh) 2017-03-15 2024-07-09 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
KR20200014279A (ko) * 2017-06-09 2020-02-10 크리티테크, 인크. 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료
SG10201913400QA (en) * 2017-06-14 2020-03-30 Crititech Inc Methods for treating lung disorders
EP3648741A4 (en) * 2017-07-07 2021-05-05 DFB Pharmaceuticals, LLC TREATMENT OF HYPERPLASTIC TISSUE GROWTH INCLUDING BENEFIT PROSTATE HYPERPLASIA (BPH) BY DIRECT INJECTION OF ANTINEOPLASTIC AGENT
WO2019067851A1 (en) 2017-09-29 2019-04-04 Crititech, Inc. CIPROFLOXACIN POLYMORPHS AND USE THEREOF
WO2019067866A1 (en) 2017-09-29 2019-04-04 Crititech, Inc. GLUCOCORTICOID PARTICLES AND THEIR USE
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
US20190209514A1 (en) 2018-01-05 2019-07-11 Crititech, Inc. Treatment of Bladder Cancer by Local Administration of Taxane Particles
CN112165949A (zh) * 2018-03-16 2021-01-01 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗宫颈上皮内瘤变(cin)和宫颈癌的局部疗法
JP7423544B2 (ja) * 2018-05-31 2024-01-29 クリティテック・インコーポレイテッド 養子細胞療法およびがんワクチンのための腫瘍特異的免疫細胞を対象から単離するための方法
US20190365698A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer
US20190365699A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Treatment of Kidney Tumors by Intratumoral Injection of Taxane Particles
CN108970835B (zh) * 2018-09-20 2020-11-17 马鞍山纽泽科技服务有限公司 一种耐高温喷射装置
WO2020072090A1 (en) 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
KR20220137019A (ko) * 2020-02-04 2022-10-11 주하이 베이하이 바이오테크 컴퍼니 리미티드 도세탁셀의 제형
KR20230044423A (ko) 2020-07-23 2023-04-04 크리티테크, 인크. 라파티닙 입자 및 이의 용도
CN115916198A (zh) * 2020-07-23 2023-04-04 科里提泰克有限公司 索拉非尼颗粒及其用途
CN113447635B (zh) * 2021-05-11 2023-09-29 江西农业大学 一种盆栽类土壤不同深度温室气体释放速率测定装置
WO2023086779A1 (en) 2021-11-10 2023-05-19 Crititech, Inc. Niraparib particles and uses thereof
KR20240095260A (ko) 2021-11-10 2024-06-25 크리티테크, 인크. 루카파립 입자 및 이의 용도
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3648698A (en) * 1969-05-23 1972-03-14 George O Doherty Surgical collection unit
DE3120047C2 (de) * 1981-05-20 1984-03-29 Sterimed Gesellschaft für medizinischen Bedarf mbH, 6600 Saarbrücken Sauggerät zum Ansaugen von Körpersekreten
JPS5958019U (ja) 1982-10-08 1984-04-16 松下電器産業株式会社 電気集塵機
US4780138A (en) * 1986-10-27 1988-10-25 Bodine Albert G Sonic apparatus and method for facilitating the extraction of minerals from ore in a leachant
US5143528A (en) 1990-02-14 1992-09-01 Challenge Industries Lint collector
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5409833A (en) * 1993-07-01 1995-04-25 Baxter International Inc. Microvessel cell isolation apparatus
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5480540A (en) 1994-10-17 1996-01-02 General Electric Company Spray apparatus for separating solids from fluids
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
JP2001513078A (ja) 1996-12-30 2001-08-28 バテル・メモリアル・インスティテュート 吸入により新生物を治療する製剤とその方法
HU230338B1 (hu) 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JPH11189403A (ja) 1997-12-25 1999-07-13 Tic:Kk 層構造型複合粒子製造装置
JP3418751B2 (ja) 1998-01-22 2003-06-23 参天製薬株式会社 フルオロメトロン懸濁型点眼剤
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
WO2000030660A2 (de) 1998-11-25 2000-06-02 Universitätsklinikum Freiburg Hyperforin als zytostatikum sowie hyperforin-salbe oder -creme als applikationsform
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
KR100752000B1 (ko) * 1999-05-27 2007-08-28 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 제조방법
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
CA2388844A1 (en) 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
SE0001543L (sv) * 2000-04-28 2001-09-10 Bst Ab Förfarande och anordning för uppsugning och transport av vätskor, företrädesvis blod
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
EP1387676A2 (en) 2001-05-01 2004-02-11 Angiotech Pharmaceuticals, Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
EP1401563B2 (en) 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Process for the production of micro and/or nano particles
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
CA2461556A1 (en) * 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
JP2003251127A (ja) 2002-03-06 2003-09-09 Kazuo Hirakawa 集塵装置
WO2003080027A1 (en) 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
GB2387781A (en) * 2002-04-25 2003-10-29 Nektar Therapeutics Uk Ltd Particulate materials
JP2005529127A (ja) 2002-04-26 2005-09-29 テバ ファーマシューティカル インダストリーズ リミティド 腫瘍内送達のためのミクロ粒子製薬組成物
US9339459B2 (en) * 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (zh) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 紫杉醇纳米微粒的制备方法及应用
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US6916389B2 (en) * 2002-08-13 2005-07-12 Nanotechnologies, Inc. Process for mixing particulates
CN2578811Y (zh) * 2002-10-24 2003-10-08 陆纪清 全闭式煤粉取样装置
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
CN102697737B (zh) 2003-04-03 2014-03-19 杰西.L.-S.奥 负载肿瘤靶向药物的颗粒
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
EP2286794B8 (en) 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US7208106B2 (en) 2003-10-24 2007-04-24 Ferro Corporation Method of forming particles
US7879360B2 (en) 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
DE10357091A1 (de) * 2003-12-06 2005-07-07 Degussa Ag Vorrichtung und Verfahren zur Abscheidung feinster Partikel aus der Gasphase
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
JP5164381B2 (ja) 2004-10-29 2013-03-21 株式会社奈良機械製作所 微細粒子の造粒方法
US20060159712A1 (en) 2004-12-14 2006-07-20 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
ES2265262B1 (es) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0608173A2 (pt) 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8118795B2 (en) * 2005-03-22 2012-02-21 Medindica-Pak, Inc Disposal chain supply systems method and apparatus
JP5635231B2 (ja) 2005-03-31 2014-12-03 リッズ エービーLidds Ab 活性物質の局所送達に基づく前立腺疾患の治療方法
CN1923189A (zh) 2005-08-30 2007-03-07 孔庆忠 一种紫杉碱类抗癌药物的缓释注射剂
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス, エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
JP2009518167A (ja) 2005-12-11 2009-05-07 エスセーエフ テクノロジーズ アクティーゼルスカブ ナノサイズ材料の製造
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101336899A (zh) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 含紫杉烷的抗癌缓释注射剂
CN101431984B (zh) 2006-03-14 2013-07-10 利德斯股份公司 生物可吸收性的控释组合物
US7964029B2 (en) * 2006-07-17 2011-06-21 Thar Instrument, Inc. Process flowstream collection system
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
DE602006012236D1 (de) * 2006-10-11 2010-03-25 Renault Trucks Mit einem passiven, schlüssellosen zugangssystem versehener lastwagen
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
EP2173732A4 (en) 2007-07-04 2011-09-07 Reddys Lab Ltd Dr PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC
CN101129338A (zh) * 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
EP2262537A1 (en) 2008-03-06 2010-12-22 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
EP2258748B1 (en) * 2008-03-24 2019-05-08 Sanyo Chemical Industries, Ltd. Resin particle and method for producing the same
JP5536654B2 (ja) 2008-09-19 2014-07-02 株式会社アクティバスファーマ 医療用複合有機化合物粉体、その製造方法ならびに懸濁液
EP2367535B1 (en) 2008-12-02 2017-02-22 Biocompatibles Uk Ltd. Pancreatic tumour treatment
PT104693B (pt) 2009-07-27 2011-11-24 Univ Lisboa Nanopartículas lipídicas semi-sólidas contendo um agente antineoplásico e seu processo de preparação
DK2470644T3 (en) 2009-08-24 2017-01-16 Baylor College Medicine GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MORE TUMOR ANTIGEN OR MORE
US20110209578A1 (en) * 2010-02-26 2011-09-01 Kuniaki Ara Nanoparticle manufacturing device and nanoparticle manufacturing method and method of manufacturing nanoparticle-dispersed liquid alkali metal
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
RU2621640C2 (ru) 2010-06-02 2017-06-06 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
CN103209710B (zh) 2010-09-21 2016-04-06 克里斯特欧德里发里有限公司 用于药物递送系统中组分的短暂连接的可调的、可生物降解的接头分子以及利用其制备的药物递送系统
US20150093440A1 (en) 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
JP2013544181A (ja) * 2010-10-29 2013-12-12 ベリコ メディカル インコーポレイティッド 液体をスプレードライするためのシステム及び方法
WO2012096995A2 (en) * 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
DK2699233T3 (en) 2011-04-20 2017-07-10 Univ Sydney PARTICULAR MATERIAL AND CELLULAR TOXIN USED TO TREAT A SOLID TUMOR
WO2013052158A2 (en) 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
MX351781B (es) 2011-06-17 2017-10-30 Berg Llc Composiciones farmaceuticas inhalables.
WO2013002636A1 (en) 2011-06-27 2013-01-03 Cristal Delivery B.V. Controlled release system
US11766459B2 (en) * 2011-07-08 2023-09-26 Jointechlabs, Inc. System and methods for preparation of adipose-derived stem cells
PT2750789T (pt) * 2011-08-31 2018-10-30 Archer Daniels Midland Co Processo de oxidação em spray para produzir ácido 2,5- furandicarboxílico a partir de hidroxi-metilfurfural
FR2980683B1 (fr) 2011-09-30 2014-11-21 Univ Paris Curie Dispositif de guidage d'un instrument medical insere dans une voie naturelle ou une voie artificielle d'un patient
CN102319898B (zh) * 2011-10-13 2013-05-08 西北工业大学 一种制备合金及金属基复合材料零部件的喷射成形系统
CN102488682A (zh) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 绿原酸的抗癌新用途
JP2013212494A (ja) * 2012-03-05 2013-10-17 Ricoh Co Ltd 樹脂微粒子の製造方法
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
CN102728414A (zh) 2012-07-07 2012-10-17 中山大学 用于制备单壁碳纳米管的催化剂的制备方法及其运用
TW201408304A (zh) 2012-08-31 2014-03-01 Cathay General Hospital 一種合併抗癌藥物及荷爾蒙之抗腎細胞癌藥物及其製造方法
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
WO2014081881A2 (en) * 2012-11-20 2014-05-30 Andrew Paul Joseph Fluid-based extractor
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6067892B2 (ja) 2013-02-28 2017-01-25 ファイザー・インク 安定性を増強した新規な液体組成物
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR ITS PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2014169137A1 (en) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
CN203699094U (zh) * 2013-10-15 2014-07-09 雷海平 新式垃圾桶及配套内桶
JP6595463B2 (ja) 2013-10-16 2019-10-23 ユニベルシテ リブレ デ ブリュッセル 気道に影響する増殖性疾患の処置に有用な製剤
CN112353943A (zh) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
KR20160101073A (ko) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015103005A1 (en) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
CN203737192U (zh) * 2014-01-20 2014-07-30 四川西汉电子科技有限责任公司 一种造粒机
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
CN203847940U (zh) 2014-06-04 2014-09-24 刘希 一种加料喷嘴调节支架
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US9533449B2 (en) * 2014-06-19 2017-01-03 Autodesk, Inc. Material deposition systems with four or more axes
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
DK3302431T3 (da) * 2015-06-04 2020-11-30 Crititech Inc Taxanpartikler og anvendelse deraf
EP3324930A2 (en) * 2015-09-16 2018-05-30 DFB Soria, LLC Delivery of drug nanoparticles and methods of use thereof
EP3352796A4 (en) 2015-09-25 2019-05-01 ZY Therapeutics Inc. PARTICLE-BASED MEDICINAL FORMULATION COMPRISING A POLYSACCHARIDE-VITAMIN CONJUGATE
DE202016006620U1 (de) 2015-10-28 2017-04-12 Qass Gmbh Vorrichtungen zum Beobachten eines Magnetfelds eines Materialvolumens
CN108473959B (zh) 2016-01-20 2023-04-21 菲特治疗公司 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
RU2737934C2 (ru) * 2016-04-04 2020-12-07 Крититек, Инк. Способы лечения солидных опухолей
CN107281502B (zh) 2016-04-05 2021-05-04 上海市肿瘤研究所 一种复合显影温敏凝胶栓塞剂、制备方法及其应用
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
BR112018015095B1 (pt) * 2016-05-12 2022-02-01 Hewlett-Packard Development Company, L.P Recipiente de material de construção de fabricação aditiva
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CN110636833B (zh) 2017-03-15 2024-07-09 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
KR20200014279A (ko) 2017-06-09 2020-02-10 크리티테크, 인크. 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료
SG10201913400QA (en) 2017-06-14 2020-03-30 Crititech Inc Methods for treating lung disorders

Also Published As

Publication number Publication date
KR102077518B1 (ko) 2020-02-14
US20180125783A1 (en) 2018-05-10
CN107743418A (zh) 2018-02-27
AU2016270549B2 (en) 2019-01-17
CA2988132A1 (en) 2016-12-08
US20170224650A1 (en) 2017-08-10
US11123322B2 (en) 2021-09-21
US10729673B2 (en) 2020-08-04
US20200163928A1 (en) 2020-05-28
DK3302431T3 (da) 2020-11-30
KR102551708B1 (ko) 2023-07-06
EP3302423B1 (en) 2022-05-25
EP3302431B1 (en) 2020-11-11
ES2833749T3 (es) 2021-06-15
EP3302780A1 (en) 2018-04-11
US10993927B2 (en) 2021-05-04
BR112017025815A2 (pt) 2018-08-14
PT3302431T (pt) 2020-11-30
HK1253020A1 (zh) 2019-06-06
CA3026454A1 (en) 2016-12-08
KR20200020995A (ko) 2020-02-26
JP6892394B2 (ja) 2021-06-23
US11291646B2 (en) 2022-04-05
CN107683174A (zh) 2018-02-09
JP2018524145A (ja) 2018-08-30
US20200405684A1 (en) 2020-12-31
KR20180013906A (ko) 2018-02-07
US20160354336A1 (en) 2016-12-08
EP3302780B1 (en) 2019-04-17
RU2750163C2 (ru) 2021-06-22
CN107683131A (zh) 2018-02-09
US20210000786A1 (en) 2021-01-07
JP2018526188A (ja) 2018-09-13
HK1253021B (zh) 2020-01-24
AU2016270549A1 (en) 2017-11-16
SG10201913947RA (en) 2020-03-30
KR102337080B1 (ko) 2021-12-08
AU2016270558B2 (en) 2020-08-13
CA3026452C (en) 2023-03-21
JP7096299B2 (ja) 2022-07-05
EP3838264A1 (en) 2021-06-23
US10751319B2 (en) 2020-08-25
US20180169058A1 (en) 2018-06-21
EP3302423A1 (en) 2018-04-11
WO2016197100A1 (en) 2016-12-08
CA3026454C (en) 2023-07-04
US20210393569A1 (en) 2021-12-23
CA3026452A1 (en) 2016-12-08
CN107683174B (zh) 2021-02-19
JP2022121532A (ja) 2022-08-19
SG10201913945QA (en) 2020-03-30
US9814685B2 (en) 2017-11-14
AU2016270558A1 (en) 2017-11-16
WO2016197101A1 (en) 2016-12-08
US20180116910A1 (en) 2018-05-03
CN107683131B (zh) 2021-09-28
US20160374953A1 (en) 2016-12-29
KR20180015635A (ko) 2018-02-13
HK1253018A1 (zh) 2019-06-06
KR20200134347A (ko) 2020-12-01
HK1253021A1 (zh) 2019-06-06
RU2017140678A (ru) 2019-07-09
JP6758325B2 (ja) 2020-09-23
WO2016197091A1 (en) 2016-12-08
JP2020203913A (ja) 2020-12-24
JP6921759B2 (ja) 2021-08-18
KR102317107B1 (ko) 2021-10-25
US9918957B2 (en) 2018-03-20
US10507195B2 (en) 2019-12-17
CN114010628A (zh) 2022-02-08
AU2016270559B2 (en) 2020-12-10
CA2988132C (en) 2021-04-27
EP3302431A1 (en) 2018-04-11
JP2018516907A (ja) 2018-06-28
KR20180016366A (ko) 2018-02-14
AU2016270559A1 (en) 2017-11-16
US20200101039A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
BR112018002569A2 (ru)
RU2017140678A3 (ru)
BR112016003711A2 (ru)
BE2015C047I2 (ru)
BE2015C044I2 (ru)
BR0003751B1 (ru)
BR0000126B1 (ru)
BR0000695B1 (ru)
BR0000763F1 (ru)
BR0001536B1 (ru)
BR0001684B1 (ru)
BR0001810B1 (ru)
BR0002033B1 (ru)
BR0002402B1 (ru)
BR0002435B1 (ru)
BR0002694B1 (ru)
BR0002802B1 (ru)
BR0002874B1 (ru)
BR0003166B1 (ru)
BR0003189B1 (ru)
BR0003208B1 (ru)
BR0008158B1 (ru)
BR0003401B1 (ru)
BR0003686B1 (ru)
BR0003746B1 (ru)